ADC Ther­a­peu­tics re­veals topline Zyn­lon­ta da­ta, $105M stock of­fer­ing

ADC Ther­a­peu­tics an­nounced a $105 mil­lion of­fer­ing af­ter shar­ing what it called pos­i­tive topline da­ta from a Phase 2 tri­al of its can­cer drug Zyn­lon­ta.

The Swiss biotech is sell­ing off 13.4 mil­lion shares for $4.90 each and pre-fund­ed war­rants to pur­chase an­oth­er 8.1 mil­lion shares for $4.81 each for cer­tain in­vestors. Its stock $AD­CT dipped around 8% on Mon­day af­ter­noon.

The com­pa­ny said Mon­day that its an­ti­body-drug con­ju­gate showed a “high re­sponse rate” in pa­tients with re­lapsed/re­frac­to­ry mar­gin­al zone lym­phoma (MZL), a rare type of non-Hodgkin lym­phoma with few treat­ment op­tions, ac­cord­ing to the com­pa­ny. Those op­tions can in­clude chemother­a­py, im­munother­a­py, surgery or Rit­ux­an. ADC CMO Mo­hamed Za­ki said in a state­ment that the com­pa­ny plans to “po­ten­tial­ly pur­sue” ap­proval for MZL if the tri­al re­sults con­tin­ue to be promis­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER